Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 46,195

Document Document Title
WO/2014/069434
[Problem] To provide a novel thiazolidinone derivative. [Solution] A thiazolidinone derivative or a pharmaceutically acceptable salt thereof represented by formula (I) or (II). (I) (II)  
WO/2014/068171
Compounds of formula I or formula II, wherein Q1Q3 and R1-R5 are as defined in the claims, exhibit CytC derived peroxidase inhibiting activity and are thus useful as CytC derived peroxidase inhibiting agents.  
WO/2014/068327
The present invention relates to the use of agents (including heparin derivatives) for the prevention and/or treatment of CNS damage.  
WO/2014/071157
The invention provides compositions and in vivo, ex vivo and in vitro methods for trans-differentiation of or re-programming mammalian cells to functional neurons. In particular, the invention provides methods for engineering non-neurona...  
WO/2014/071005
Described herein are compositions and methods for treating or preventing ischemic injury. In particular, the methods and compositions relate to the use of a neuroprotective steroid, such as a progestogen, such as progesterone or allopreg...  
WO/2014/071282
This disclosure relates to methods for improving neural function in a mammal with a proteinopathy comprising administering a therapeutically effective amount of an agent that increases glucocerebrosidase activity in the mammal. Also disc...  
WO/2014/065434
The present invention provides a compound which has an effect of inhibiting amyloid beta production, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production,...  
WO/2014/066659
The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of disease.  
WO/2014/066304
Disclosed herein are compounds, compositions, formulations, kits and methods of treatment useful for treating or preventing one or more hyperproliferative disorders, e.g., cancer or a neurological disease or disorder.  
WO/2014/064257
The invention provides a conjugate comprising(i) a selectivity agent which binds specifically to one or more neurotransmitter transporters selected from the group consisting of a dopamine transporter (DAT), serotonine transporter (SERT) ...  
WO/2014/065194
Provided are a nerve growth inhibitor and a cutaneous-sensory-irritation inhibitor, with which cutaneous-sensory irritation and nerve growth based on newly found nerve growth mechanisms can be effectively inhibited. This nerve growth inh...  
WO/2014/064028
This invention relates to a new medical use for certain chemical compounds and pharmaceutical compositions containing them. The invention relates to compounds which are mGlu2/3 negative allosteric modulators for use in the treatment of A...  
WO/2014/063587
The present invention relates to the field of pharmaceutical chemistry and pharmacotherapeutics, and in particular to compounds of general formula I, racemates, R-isomers, S-isomers, and pharmaceutically acceptable salts thereof and thei...  
WO/2014/066659
The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of disease.  
WO/2014/063312
The present invention relates to the use of salvianolic acid A in the preparation of drugs for preventing and/or treating cerebral microvascular thromboembolic diseases.  
WO/2014/065270
 Provided is a therapeutic agent for neurodegenerative disorders and psychiatric disorders related to mGluR5, the therapeutic agent comprising a compound represented by formula (I) or a pharmaceutically acceptable salt of the same (in ...  
WO/2014/065348
A fragment peptide that is composed of a part of HMGB1 protein and has a proper length is synthesized, and it is confirmed that the peptide has a therapeutic effect on spinal cord injury.  
WO/2014/066318
The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therape...  
WO/2014/065413
 A compound represented by general formula [I] or a pharmaceutically acceptable salt thereof. (In the formula, each symbol is as defined in the description.)  
WO/2014/063199
Novel benzofuran derivatives are disclosed. The derivatives have S1P1 receptor activity and/or disease modifying activity and find use in the treatment of conditions or diseases associated with the immune, vascular and nervous systems in...  
WO/2014/064258
The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which i...  
WO/2014/064166
Mixed inhibitors of aminopeptidase N and of neprilysine are described. Pharmaceutical compositions containing at least one of these compounds, used alone or in combination with morphine and derivatives thereof, endocannabinoids and inhib...  
WO/2014/065669
The invention relates to treatments for cognitive decline and/or memory impairment based on reducing the extracellular matrix in the hippocampus. Improved compositions are provided for such treatments. The invention also relates to detec...  
WO/2014/066132
The present invention provides compounds of Formula I useful as BACE inhibitors in the treatment of e.g. Alzheimer's disease : wherein A is selected from the group consisting of; of; R1 is H or F; R2 is H, -OCH3, C1-C3 alkyl,; R3 is H, -...  
WO/2014/065710
The invention relates to novel (3-arylsulfonyl-quinoline-8-yl)-dialkyl-amines of general formula 1, or pharmaceutically acceptable salts thereof, which are selective serotonin 5-HT6 receptor antagonists. The compounds can be used as a me...  
WO/2014/065606
The present invention provides a composition for preventing and treating nerve disease, comprising osmotin and an inhibitor for inhibiting activity or expression of gamma-aminobutyric acid (GABA) B receptor proteins so as to provide the ...  
WO/2014/066208
The present invention provides methods of providing rapid relief of motor fluctuations in a Parkinson's disease patient. The methods of the invention comprise pulmonary administration of levodopa by inhalation at therapeutically effectiv...  
WO/2014/066695
Disclosed is a compound of formula (I). or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions including the compound of formula (I) and methods of using the compound of formula (I).  
WO/2014/066686
Provided are method of treatment with MANF. In certain embodiments, the invention provides a method of treating Parkinson's disease by administering MANF to the substantia nigra.  
WO/2014/064038
The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula (I) as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are su...  
WO/2014/064162
Neprilysin inhibitors are described. The compounds or compositions containing them can be used as antidiarrheal agents, antisecretory agents, anxiolytic agents, antidepressants, cicatrizants, fluid effusion reducers or in the treatment o...  
WO/2014/060941
Disclosed are compounds of formula I, their pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of...  
WO/2014/060394
The present invention relates to ethynyl derivatives of formula (I) or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. It ha...  
WO/2014/062548
The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the ...  
WO/2014/062870
A method of treating brain injury or brain trauma in an animal by administering to an animal TSG-6 protein or a biologically active fragment, derivative, or analogue thereof.  
WO/2014/061693
The purpose of the present invention is to provide a novel compound that has an ACC2 inhibitory activity. Also provided is a medicinal composition containing the compound. A compound represented by formula (I) or a pharmaceutically accep...  
WO/2014/060509
The use of a bioactivated phytochemical is disclosed for preventing and treating neurodegenerative diseases, such as Parkinson's disease and multiple sclerosis. In particular, said bioactivated phytochemical is Rs-Glucoraphanin bioactiva...  
WO/2014/063071
Depression and PTSD are treated by administration of hCG, or an hCG analog, or a prodrug or metabolite of hCG or an hCG analog, in an amount equivalent to a subcutaneous dose of 50 200 IU, preferably 120 170 IU, more preferably 140 160 I...  
WO/2014/063057
The present invention provides a method for treating, alleviating, reversing or delaying progression of at least one symptom of Parkinson's Disease in a subject in need thereof by administering to the subject an effective amount of a 2-a...  
WO/2014/060386
The present invention provides compounds of formula (I), wherein Z, R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. Further the present invention is concerned with the manufacture ...  
WO/2014/060384
The present invention relates to ethynyl derivatives of formula (I) wherein Y is N or CH R1 is fluoro or chloro or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optic...  
WO/2014/060112
The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or ...  
WO/2014/060398
The present invention relates to ethynyl derivatives of formula (I) wherein Y is N or CH R1 is fluoro or chloro R2 is hydrogen or methyl or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its correspondin...  
WO/2014/060431
New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositid...  
WO/2014/060501
The invention relates to an agent for treating migraines or migraine pain. The invention also relates to an agent for the preventative treatment of chronic migraines or chronic migraine pain. According to the invention, the agent contain...  
WO/2014/061676
Provided is a compound useful as a prophylactic or therapeutic agent for neurodegenerative diseases and others or a salt of the compound. The present invention relates to a compound represented by formula (I) [wherein each symbol is as d...  
WO/2014/060371
The present invention relates to the use of novel compounds of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.  
WO/2014/059512
In an aspect, a formulation is provided that comprises at least one active substance and at least one coat comprising Eudragit E (dimethylaminoethyl methacrylate copolymer), wherein the formulation is free of any active substance externa...  
WO/2014/061764
A compound having an exceptional blood-sugar-reducing effect and represented by general formula (I), and a pharmaceutically acceptable salt thereof. In the formula, X is =C(R8)-, -CH(R8)-, =N-, or -O-; Y is =C(R9)-, -CH(R9)-, or =N-; Z i...  
WO/2014/062044
Invention is related to novel compounds - fluorinated benzenesulfonamides of general formula (I). The compounds can be used in biomedicine as active ingredients in pharmaceutical formulations, because they inhibit enzymes which participa...  

Matches 351 - 400 out of 46,195